STOCK TITAN

[Form 4] Vor Biopharma Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Vor Biopharma (VOR) insider filing reports open‑market sales by an affiliate of director Reid Hoffman totaling 96,657 shares across 10/10–10/14/2025, executed at weighted average prices disclosed in the filing. Following these transactions, 1,278,118 shares were beneficially owned.

The securities are held by Reprogrammed Interchange LLC; Mr. Hoffman may be deemed a beneficial owner through shared control and indirect pecuniary interest and disclaims beneficial ownership except to the extent of his interest. The filing was made by more than one reporting person.

Vor Biopharma (VOR) dichiarazione di insider riferisce vendite sul mercato aperto da un'affiliata del direttore Reid Hoffman per un totale di 96.657 azioni nell'arco del periodo 10/10–10/14/2025, eseguite ai prezzi medi ponderati indicati nella dichiarazione. A seguito di queste operazioni, 1.278.118 azioni sono state detenute beneficiariamente.

Le azioni sono detenute da Reprogrammed Interchange LLC; il signor Hoffman potrebbe essere considerato proprietario beneficiario attraverso il controllo condiviso e un interesse pecuniario indiretto e nega la proprietà effettiva salvo per l'interesse in suo possesso. La dichiarazione è stata presentata da più di un soggetto responsabile della segnalazione.

Vor Biopharma (VOR) presentación de insider afirma ventas en el mercado abierto por una afiliada del director Reid Hoffman por un total de 96.657 acciones a lo largo del periodo 10/10–10/14/2025, ejecutadas a los precios medios ponderados que se detallan en la declaración. Tras estas operaciones, 1.278.118 acciones fueron poseídas de forma beneficiosa.

Los valores están en posesión de Reprogrammed Interchange LLC; el señor Hoffman podría ser considerado un beneficiario por control compartido y por interés pecuniario indirecto y discute no ser propietario beneficioso salvo en la medida de su interés. La declaración fue presentada por más de una persona reportante.

Vor Biopharma (VOR) 내부자 공시서는 이사 Reid Hoffman의 계열사가 10/10–10/14/2025 기간에 걸쳐 96,657주의 공개시장 매도를 총액으로 보고했으며, 공시에 기재된 가중평균가로 체결되었습니다. 이 거래들 이후 1,278,118주가 유익하게 보유되었습니다.

주식은 Reprogrammed Interchange LLC가 보유하고 있으며, Hoffman 씨는 공동 지배 및 간접 재정적 이해관계를 통해 유익한 소유자로 간주될 수 있고 그 소유권을 부인합니다. 공시는 다수의 보고자에 의해 이루어졌습니다.

Vor Biopharma (VOR) déclaration d'initiés rapporte des ventes sur le marché par une affiliée du directeur Reid Hoffman pour un total de 96 657 actions sur la période du 10/10–14/10/2025, exécutées à des prix moyens pondérés indiqués dans le dépôt. À la suite de ces transactions, 1 278 118 actions ont été détenues bénéficiairement.

Les valeurs sont détenues par Reprogrammed Interchange LLC; M. Hoffman peut être considéré comme bénéficiaire par contrôle partagé et intérêt financier indirect, et déclare ne pas détenir la propriété bénéficiaire sauf dans la mesure de son intérêt. Le dépôt a été effectué par plus d'une personne déclarant.

Vor Biopharma (VOR) Insider-Deklaration berichtet über Verkäufe im freien Markt durch eine Tochtergesellschaft des Direktors Reid Hoffman insgesamt 96.657 Aktien über den Zeitraum 10/10–14/10/2025, die zu in der Akte offengelegten gewichteten Durchschnittspreisen durchgeführt wurden. Nach diesen Transaktionen befanden sich 1.278.118 Aktien im wirtschaftlichen Eigentum.

Die Wertpapiere werden von Reprogrammed Interchange LLC gehalten; Herr Hoffman könnte aufgrund gemeinsamer Kontrolle und indirekter vermögensrechtlicher Interessen als wirtschaftlich Eigentümer gelten und bestreitet das wirtschaftliche Eigentum bis zur Höhe seines Interesses. Die Erklärung wurde von mehr als einer meldenden Person abgegeben.

Vor Biopharma (VOR) تقديم معلومات للمُعلن عن insider يشير إلى عمليات بيع في السوق المفتوح من قبل شركة تابعة للمدير ريد هوفمان بإجمالي 96,657 سهماً عبر الفترة 10/10–14/10/2025، مُنفذة عند أسعار متوسطة وزنهذه مذكورة في الملف. عقب هذه المعاملات، تم امتلاك 1,278,118 سهماً بشكل مستفيد.

يتم الاحتفاظ بالأوراق المالية بواسطة Reprogrammed Interchange LLC؛ قد يُ regarded السيد هوفمان كمالك مستفيد من خلال سيطرة مشتركة ومصلحة مالية غير مباشرة وينفي الملكية المفيدة باستثناء مدى مصالحه. تم تقديم الملف من قبل أكثر من شخص مُبلغ.

Vor Biopharma (VOR) 的内幕披露报告显示,来自董事 Reid Hoffman 的一家公司在公开市场的出售共计 96,657 股,覆盖时间为 2025/10/10–2025/10/14,交易价格按披露文件中的加权平均价格执行。完成这些交易后,拥有权益的股份为 1,278,118 股

这些证券由 Reprogrammed Interchange LLC 持有;Hoffman 先生可能通过共同控制和间接的金钱利益被视为受益所有人,且除他本人权益外,否认其他受益所有权。 filing 由不止一位报告人提交。

Positive
  • None.
Negative
  • None.

Insights

Director-affiliated entity sold 96,657 VOR shares; 1,278,118 remain.

This Form 4 lists multiple open‑market sales over several days, each reported with weighted average prices and footnoted price ranges. Such filings document changes in insider-affiliated holdings and the remaining beneficial ownership after the trades.

The shares are held by Reprogrammed Interchange LLC, with Reid Hoffman potentially deemed a beneficial owner via shared control; he disclaims beneficial ownership except for his pecuniary interest. Actual market impact depends on trade size relative to float and daily volume, which are not provided in the excerpt.

Subsequent ownership stands at 1,278,118 shares after the reported sales. Any further activity would appear in future ownership reports if and when filed.

Vor Biopharma (VOR) dichiarazione di insider riferisce vendite sul mercato aperto da un'affiliata del direttore Reid Hoffman per un totale di 96.657 azioni nell'arco del periodo 10/10–10/14/2025, eseguite ai prezzi medi ponderati indicati nella dichiarazione. A seguito di queste operazioni, 1.278.118 azioni sono state detenute beneficiariamente.

Le azioni sono detenute da Reprogrammed Interchange LLC; il signor Hoffman potrebbe essere considerato proprietario beneficiario attraverso il controllo condiviso e un interesse pecuniario indiretto e nega la proprietà effettiva salvo per l'interesse in suo possesso. La dichiarazione è stata presentata da più di un soggetto responsabile della segnalazione.

Vor Biopharma (VOR) presentación de insider afirma ventas en el mercado abierto por una afiliada del director Reid Hoffman por un total de 96.657 acciones a lo largo del periodo 10/10–10/14/2025, ejecutadas a los precios medios ponderados que se detallan en la declaración. Tras estas operaciones, 1.278.118 acciones fueron poseídas de forma beneficiosa.

Los valores están en posesión de Reprogrammed Interchange LLC; el señor Hoffman podría ser considerado un beneficiario por control compartido y por interés pecuniario indirecto y discute no ser propietario beneficioso salvo en la medida de su interés. La declaración fue presentada por más de una persona reportante.

Vor Biopharma (VOR) 내부자 공시서는 이사 Reid Hoffman의 계열사가 10/10–10/14/2025 기간에 걸쳐 96,657주의 공개시장 매도를 총액으로 보고했으며, 공시에 기재된 가중평균가로 체결되었습니다. 이 거래들 이후 1,278,118주가 유익하게 보유되었습니다.

주식은 Reprogrammed Interchange LLC가 보유하고 있으며, Hoffman 씨는 공동 지배 및 간접 재정적 이해관계를 통해 유익한 소유자로 간주될 수 있고 그 소유권을 부인합니다. 공시는 다수의 보고자에 의해 이루어졌습니다.

Vor Biopharma (VOR) déclaration d'initiés rapporte des ventes sur le marché par une affiliée du directeur Reid Hoffman pour un total de 96 657 actions sur la période du 10/10–14/10/2025, exécutées à des prix moyens pondérés indiqués dans le dépôt. À la suite de ces transactions, 1 278 118 actions ont été détenues bénéficiairement.

Les valeurs sont détenues par Reprogrammed Interchange LLC; M. Hoffman peut être considéré comme bénéficiaire par contrôle partagé et intérêt financier indirect, et déclare ne pas détenir la propriété bénéficiaire sauf dans la mesure de son intérêt. Le dépôt a été effectué par plus d'une personne déclarant.

Vor Biopharma (VOR) Insider-Deklaration berichtet über Verkäufe im freien Markt durch eine Tochtergesellschaft des Direktors Reid Hoffman insgesamt 96.657 Aktien über den Zeitraum 10/10–14/10/2025, die zu in der Akte offengelegten gewichteten Durchschnittspreisen durchgeführt wurden. Nach diesen Transaktionen befanden sich 1.278.118 Aktien im wirtschaftlichen Eigentum.

Die Wertpapiere werden von Reprogrammed Interchange LLC gehalten; Herr Hoffman könnte aufgrund gemeinsamer Kontrolle und indirekter vermögensrechtlicher Interessen als wirtschaftlich Eigentümer gelten und bestreitet das wirtschaftliche Eigentum bis zur Höhe seines Interesses. Die Erklärung wurde von mehr als einer meldenden Person abgegeben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Reprogrammed Interchange LLC

(Last) (First) (Middle)
101 MISSION STREET, SUITE 1000

(Street)
SAN FRANCISCO CA 94105

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Vor Biopharma Inc. [ VOR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/10/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/10/2025 S 40,983 D $30.9673(1) 1,333,792(2) D
Common Stock 10/13/2025 S 19,672 D $32.3587(3) 1,314,120(2) D
Common Stock 10/13/2025 S 2,334 D $33.0873(4) 1,311,786(2) D
Common Stock 10/14/2025 S 33,668 D $30.3192(5) 1,278,118(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
Reprogrammed Interchange LLC

(Last) (First) (Middle)
101 MISSION STREET, SUITE 1000

(Street)
SAN FRANCISCO CA 94105

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Hoffman Reid

(Last) (First) (Middle)
101 MISSION STREET, SUITE 1000

(Street)
SAN FRANCISCO CA 94105

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. This transaction was executed in multiple trades at prices ranging from $30.68 to $31.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
2. The securities are held by Reprogrammed Interchange LLC ("Reprogrammed"). Reid Hoffman may be deemed a beneficial owner of securities held by Reprogrammed by virtue of his shared control over and indirect pecuniary interest in Reprogrammed. Mr. Hoffman disclaims beneficial ownership of the securities held by Reprogrammed, except to the extent of his pecuniary interest therein.
3. This transaction was executed in multiple trades at prices ranging from $32.00 to $32.98. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
4. This transaction was executed in multiple trades at prices ranging from $33.00 to $33.135. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
5. This transaction was executed in multiple trades at prices ranging from $30.00 to $30.86. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
/s/ Reid Hoffman 10/15/2025
/s/ Frank Huang, Manager of Reprogrammed Interchange LLC 10/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many VOR shares were sold in the reported insider transactions?

The filing reports sales totaling 96,657 shares executed between 10/10/2025 and 10/14/2025.

What is the beneficial ownership after the reported VOR trades?

Beneficial ownership after the transactions is 1,278,118 shares.

Who holds the reported VOR securities?

The securities are held by Reprogrammed Interchange LLC. Reid Hoffman may be deemed a beneficial owner through shared control and indirect pecuniary interest and disclaims beneficial ownership except to the extent of his interest.

Were the VOR sales executed in multiple trades?

Yes. Each day’s weighted average price is footnoted, stating execution in multiple trades within disclosed price ranges.

Was the Form 4 filed by more than one reporting person?

Yes. The filing indicates it was filed by more than one reporting person and includes signatures from Reid Hoffman and a manager of Reprogrammed Interchange LLC.

On which dates did the VOR insider sales occur?

Reported transaction dates are 10/10/2025, 10/13/2025 (two entries), and 10/14/2025.
Vor Biopharma Inc.

NASDAQ:VOR

VOR Rankings

VOR Latest News

VOR Latest SEC Filings

VOR Stock Data

201.71M
5.63M
39.09%
43.63%
15.62%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CAMBRIDGE